DermTech has filed a patent for a method of detecting skin cancer, specifically cutaneous T cell lymphoma (CTCL), mycosis fungoides (IVIF), or Sézary syndrome (SS), based on molecular risk factors. The method involves isolating nucleic acids from a skin sample, measuring the expression level of target genes associated with CTCL, and using a software program to evaluate the gene expression signature to determine the presence or progression of CTCL. GlobalData’s report on DermTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on DermTech, predictive cancer diagnosis models was a key innovation area identified from patents. DermTech's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method of analyzing gene expression signature for ctcl detection
A recently filed patent (Publication Number: US20230142201A1) describes a method for analyzing a gene expression signature associated with cutaneous T cell lymphoma (CTCL) in a skin sample. The method involves isolating nucleic acids from the skin sample obtained from a subject suspected of having CTCL using an adhesive patch. The patch is applied to a skin region and then removed, retaining the adhered skin sample cells. The expression level of a panel of target genes known to be upregulated or downregulated in CTCL is measured, and a software program or module is used to evaluate the gene expression levels and determine the gene expression signature of the skin sample. Based on this signature, a sample score is provided, indicating the presence or absence and/or progression of CTCL.
The method can be used with mRNA as the nucleic acids and does not require the presence of melanocytes in the skin sample. Multiple adhesive patches can be used to obtain skin sample cells from different regions. The method is applicable to skin lesions and can be used to guide the administration of CTCL treatment, which may include steroids, interferon, chemotherapy, phototherapy, radiation therapy, or a bone marrow transplant. The specific types of CTCL that can be analyzed using this method include mycosis fungoides and Sézary syndrome.
In addition to the method, the patent also describes a kit for determining the presence of CTCL in a skin sample. The kit includes an adhesive patch, a nucleic acid isolation reagent, and a plurality of probes that recognize target genes associated with CTCL.
The panel of target genes used in the method can include genes encoding saposin-like proteins, FYN-binding protein family members, TEC kinase family members, STATs, TRAF3 interacting proteins, CXC chemokine family members, modulators of cell death, antimicrobials, cytokines, DNA-binding proteins, or combinations thereof. At least three target genes are recommended, with specific examples including FYB, GNLY, ITK, STAT5, TRAF3IP3, CXCL10, CXCL8, TNF, IL26, DNM3, and TNFSF11.
The software program or module used to evaluate the gene expression levels can apply various models, such as random forest, boosting, logit, lasso, or combinations thereof. Additionally, the method can involve detecting mutational changes in other target genes and using the software program or module to evaluate these changes in determining the gene expression signature.
Overall, this patent presents a method and kit for analyzing gene expression signatures associated with CTCL in skin samples, providing a potential tool for diagnosing and guiding the treatment of this type of lymphoma.